Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Any differences are carefully evaluated by manufacturers and reviewed by the FDA to ensure the biosimilar meets the Agency’s appropriately high approval standards. According to Gen Consulting Company, the global biosimilars market is projected to reach USD 71,843 million, recording a CAGR of approximately 28.9 percent from 2022 to 2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global biosimilars market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the biosimilars industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, application, and region. The global market for biosimilars can be segmented by type: fusion protein, monoclonal antibodies, recombinant growth factors, recombinant hormones, others. Globally, the monoclonal antibodies segment made up the largest share of the biosimilars market. Biosimilars market is further segmented by application: autoimmune and inflammatory, blood disorders, diabetes, growth hormone deficiency, infectious diseases, oncology, others. The oncology segment captured the largest share of the market in 2021. Based on region, the biosimilars market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). According to the research, Europe had the largest share in the global biosimilars market.

By type:
– fusion protein
– monoclonal antibodies
– recombinant growth factors
– recombinant hormones
– others

By application:
– autoimmune and inflammatory
– blood disorders
– diabetes
– growth hormone deficiency
– infectious diseases
– oncology
– others

By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)

The report also provides a detailed analysis of several leading biosimilars market vendors that include 3SBio Inc., ALVOTECH ehf., Amgen Inc., Biocad CJSC, Biocon Limited, Bio-Thera Solutions, Ltd.,, Boehringer Ingelheim Pharmaceuticals, Inc., Celltrion, Inc., Chong Kun Dang pharmaceutical Corp, CinnaGen Co., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Fresenius Kabi AG, Fujifilm Kyowa Kirin Biologics Co., Ltd., Innovent Biologics, Inc., LG Chem Ltd., Mylan N.V., Nanjing Shunxin Pharmaceuticals Co., Ltd., Outlook Therapeutics, Inc., Pfizer Inc., Reliance Life Sciences, Samsungbioepis Co., Ltd., Sandoz International GmbH, Shanghai Henlius Biotech, Inc., Suzhou Union Biopharm Co., Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global biosimilars market.
– To classify and forecast the global biosimilars market based on type, application, region.
– To identify drivers and challenges for the global biosimilars market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biosimilars market.
– To identify and analyze the profile of leading players operating in the global biosimilars market.

Why Choose This Report
– Gain a reliable outlook of the global biosimilars market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.